These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38355768)

  • 1. Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics.
    Dammak S; Gulstene S; Palma DA; Mattonen SA; Senan S; Ward AD
    Sci Rep; 2024 Feb; 14(1):3758. PubMed ID: 38355768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
    Mattonen SA; Palma DA; Johnson C; Louie AV; Landis M; Rodrigues G; Chan I; Etemad-Rezai R; Yeung TP; Senan S; Ward AD
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1121-8. PubMed ID: 26907916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Med Phys; 2014 Mar; 41(3):033502. PubMed ID: 24593744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
    De Bruycker A; Schneiders F; Gulstene S; Moghanaki D; Louie A; Palma D; Senan S
    Lung Cancer; 2024 Jul; 193():107848. PubMed ID: 38908164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.
    Qin Q; Shi A; Zhang R; Wen Q; Niu T; Chen J; Qiu Q; Wan Y; Sun X; Xing L
    Thorac Cancer; 2020 Apr; 11(4):964-972. PubMed ID: 32061061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics-based Assessment of Radiation-induced Lung Injury After Stereotactic Body Radiotherapy.
    Moran A; Daly ME; Yip SSF; Yamamoto T
    Clin Lung Cancer; 2017 Nov; 18(6):e425-e431. PubMed ID: 28623121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the predictive value of RECIST criteria following stereotactic lung radiation?
    Gulstene S; Lang P; Melody Qu X; Laba JM; Yaremko BP; Rodrigues GB; Yu E; Qiabi M; Nayak R; Malthaner RA; Fortin D; Warner A; Inculet RI; Palma DA
    Radiother Oncol; 2024 Jan; 190():109976. PubMed ID: 37918636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients With Non-Small Cell Lung Cancer (NSCLC).
    Lee K; Le T; Hau E; Hanna GG; Gee H; Vinod S; Dammak S; Palma D; Ong A; Yeghiaian-Alvandi R; Buck J; Lim R
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):40-59. PubMed ID: 34879247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
    Yang H; Wang L; Shao G; Dong B; Wang F; Wei Y; Li P; Chen H; Chen W; Zheng Y; He Y; Zhao Y; Du X; Sun X; Wang Z; Wang Y; Zhou X; Lai X; Feng W; Shen L; Qiu G; Ji Y; Chen J; Jiang Y; Liu J; Zeng J; Wang C; Zhao Q; Yang X; Hu X; Ma H; Chen Q; Chen M; Jiang H; Xu Y
    Front Oncol; 2022; 12():967360. PubMed ID: 35982975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
    Starkov P; Aguilera TA; Golden DI; Shultz DB; Trakul N; Maxim PG; Le QT; Loo BW; Diehn M; Depeursinge A; Rubin DL
    Br J Radiol; 2019 Feb; 92(1094):20180228. PubMed ID: 30457885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
    Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomic analysis for early differentiation of lung cancer recurrence from fibrosis in patients treated with lung stereotactic ablative radiotherapy.
    Kunkyab T; Mou B; Jirasek A; Haston C; Andrews J; Thomas S; Hyde D
    Phys Med Biol; 2023 Aug; 68(16):. PubMed ID: 37164024
    [No Abstract]   [Full Text] [Related]  

  • 18. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
    Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?
    Mattonen SA; Ward AD; Palma DA
    Br J Radiol; 2016 Sep; 89(1065):20160113. PubMed ID: 27245137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.